Substance / Medication

Pazopanib hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Safety and efficacy of cryoablation of soft-tissue tumours: a systematic review.
Bodard Sylvain, Marcelin Clement, Kastler Adrian et al. · Br J Radiol · 2025
PMID: 38588564Meta-AnalysisFull text (PMC)
Analytical control of process impurities in Pazopanib hydrochloride by impurity fate mapping.
Li Yan, Liu David Q, Yang Shawn et al. · J Pharm Biomed Anal · 2010
PMID: 20189340Observational
[Pharmacological profile and clinical results in advanced soft tissue sarcoma patients of pazopanib hydrochloride (Votrient(®))].
Arai Hiroyuki, Fukasawa Nobuaki, Ueta Fumie · Nihon Yakurigaku Zasshi · 2013
PMID: 23302947Review
Supersaturated Liquid Formulation of Pazopanib Hydrochloride Loaded with Synergistic Precipitation Inhibitors.
Park Jin Woo, Lee Sa-Won, Lee Jun Hak et al. · Molecules · 2024
PMID: 39598656OtherFull text (PMC)
Solubility and bioavailability improvement of pazopanib hydrochloride.
Herbrink Maikel, Groenland Stefanie L, Huitema Alwin D R et al. · Int J Pharm · 2018
PMID: 29680279Other
Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process.
Liu David Q, Chen Ted K, McGuire Michael A et al. · J Pharm Biomed Anal · 2009
PMID: 19427156Other
Characterization of forced degradation products of pazopanib hydrochloride by UHPLC-Q-TOF/MS and in silico toxicity prediction.
Patel Prinesh N, Kalariya Pradipbhai D, Sharma Mahesh et al. · J Mass Spectrom · 2015
PMID: 26349647Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Pazopanib hydrochloride (substance)
SNOMED CT
735169009
UMLS CUI
C1882305

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.